Search
for
Sort by
Research 31–60 of 33
- Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- 138: Induction of cellular senescence and hair follicle stem cell dysfunction upon p14ARF and p16Ink4a expression in the skin
- Adverse Hair Reactions to New Targeted Therapies for Cancer
- The Use of Stem Cell Differentiation Stage Factors (SCDSFs) Taken from Zebrafish Embryos during Organogenesis and Their Role in Regulating the Gene Expression of Normal and Pathological (Stem) Cells
- The PDGF/PDGFR pathway as a drug target
- Alopecia in patients treated with molecularly targeted anticancer therapies
- Stem Cell-Based Hair Cell Regeneration and Therapy in the Inner Ear
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs
- Dermatologic Adverse Events from Cancer Treatments
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- Chemotherapy and the Skin: Understanding Dermatologic Side Effects
- STABILITY INDICATING AN LC-ESI-MS/MS METHOD FOR THE QUANTIFICATION OF MINOXIDIL IN PHARMACEUTICAL DOSAGE FORMS
- Index
- Tyrosine Kinase Inhibitors against Cancer: Their Safety in 216 Moroccan Patients
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies
- Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
- Targeting Wnt Signaling for Gastrointestinal Cancer Therapy: Present and Evolving Views
- Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
- Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022
- Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
- Poster Presentations
- The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus
- Management of Dermatologic Toxicities
- Management of Skin Toxicities in Cancer Treatment: An Australian/New Zealand Perspective
- Molecular Mechanisms of Vitexin: An Update on Its Anti-Cancer Functions
- Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital
- Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment